Bioleap
Bioleap is revolutionizing immunotherapy with precision biosimulation and next-generation analytics. They empower therapeutic development using highly detailed mechanistic models with Hybrid-AI, achieving 100x better prediction accuracy and reducing data requirements by 20-fold. Their platform integrates siloed data into a single mathematical framework, better resembles human biological systems, and provides detailed mechanistic insights to inform key decisions across the drug development pipeline. Bioleap's validated platform has been tested across 10,000 conditions, accelerating pre-clinical research, extracting insights from existing data, improving patient stratification, optimizing dosing strategies, and supporting data-driven clinical trials. They develop the next generation of biologics using proprietary in-silico R&D platforms leveraging physics-first biophysical models and AI.
Industries
Nr. of Employees
small (1-50)
Bioleap
Products
In-silico R&D simulation platform for biologics
A proprietary computational platform combining physics-first biophysical models and machine learning to support biologics development, preclinical simulation, patient stratification, dosing optimization, and combination therapy assessment.
In-silico R&D simulation platform for biologics
A proprietary computational platform combining physics-first biophysical models and machine learning to support biologics development, preclinical simulation, patient stratification, dosing optimization, and combination therapy assessment.
Services
In-silico R&D platform access and modeling services
Provision of a computational R&D platform that applies physics-first biophysical models combined with machine learning to design and evaluate biologics and cell therapies, simulate preclinical scenarios, and support clinical strategy.
Proof-of-concept and validation studies
Conducting POC simulation studies and validation runs across large condition sets to demonstrate model performance and support collaboration or partnership engagements.
In-silico R&D platform access and modeling services
Provision of a computational R&D platform that applies physics-first biophysical models combined with machine learning to design and evaluate biologics and cell therapies, simulate preclinical scenarios, and support clinical strategy.
Proof-of-concept and validation studies
Conducting POC simulation studies and validation runs across large condition sets to demonstrate model performance and support collaboration or partnership engagements.
Expertise Areas
- In-silico biologics R&D
- Mechanistic modeling and QSP
- Hybrid AI for biomedical simulation
- Virtual patient simulation and stratification
Key Technologies
- Hybrid mechanistic + machine-learning models
- Physics-based biophysical modeling
- Quantitative systems pharmacology (QSP)
- Virtual patient cohort simulation